CytomX Therapeutics (NASDAQ:CTMX) Receives “Neutral” Rating from HC Wainwright

CytomX Therapeutics (NASDAQ:CTMX)‘s stock had its “neutral” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports.

CytomX Therapeutics Trading Up 0.9 %

Shares of CytomX Therapeutics stock opened at $1.14 on Tuesday. CytomX Therapeutics has a 12 month low of $0.83 and a 12 month high of $5.85. The stock has a 50 day moving average of $1.06 and a 200 day moving average of $1.17. The firm has a market cap of $89.22 million, a PE ratio of 6.71 and a beta of 1.03.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The firm had revenue of $33.43 million during the quarter, compared to the consensus estimate of $18.92 million. During the same period in the prior year, the company earned $0.04 EPS. As a group, equities research analysts forecast that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC increased its stake in CytomX Therapeutics by 1.4% during the second quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock worth $3,324,000 after acquiring an additional 37,739 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of CytomX Therapeutics by 32.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,644,168 shares of the biotechnology company’s stock valued at $1,940,000 after purchasing an additional 405,669 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of CytomX Therapeutics by 1.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 16,359 shares during the last quarter. Congress Park Capital LLC raised its holdings in CytomX Therapeutics by 5.4% during the 3rd quarter. Congress Park Capital LLC now owns 1,216,008 shares of the biotechnology company’s stock valued at $1,435,000 after buying an additional 62,788 shares during the period. Finally, Geode Capital Management LLC lifted its position in CytomX Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after buying an additional 34,032 shares during the last quarter. Institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.